IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 76.5% during the 4th quarter, Holdings Channel reports. The firm owned 27,288 shares of the medical research company’s stock after selling 89,057 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in IQVIA were worth $5,416,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of IQV. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at about $33,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. grew its holdings in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. raised its position in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 99 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Stock Down 0.9 %

Shares of IQV opened at $208.13 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a fifty day simple moving average of $200.53 and a two-hundred day simple moving average of $219.80. The company has a market capitalization of $37.78 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.18 EPS for the current year.

Insider Buying and Selling

In related news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.